ERK5/BMK1 is a novel target of the tumor suppressor VHL: Implication in clear cell renal carcinoma

Neoplasia (United States)

Volumn 15, Issue 6, 2013, Pages 649-659

  Arias González, Laura ^a   Moreno Gimeno, Inmaculada ^a   Del Campo, Antonio Rubio ^b   Serrano Oviedo, Leticia ^b   Valero, María Llanos ^a   Esparís Ogando, Azucena ^c   de la Cruz Morcillo, Miguel Ángel ^a   Melgar Rojas, Pedro ^a   García Cano, Jesús ^a   José Cimas, Francisco ^a   Ruiz Hidalgo, María José ^d   Prado, Alfonso ^e   Callejas Valera, Juan Luis ^a   Nam Cha, Syong Hyun ^f   Giménez Bachs, José Miguel ^b   Salinas Sánchez, Antonio S ^b   Pandiella, Atanasio ^c   Del Peso, Luis ^e   Sánchez Prieto, Ricardo ^a  

^a University of Castilla La Mancha   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d CRIB UCLM   (Spain)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^f CHUA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; PROTEASOME; PUROMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUBULIN; UBIQUITIN PROTEIN LIGASE E3; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; TUMOR GROWTH; VON HIPPEL LINDAU GENE; WESTERN BLOTTING; WOUND HEALING;

EID: 84878628640     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121896     Document Type: Article

References (58)

1. Nishimoto S and Nishida E (2006). MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 7, 782-786.
2. Abe J, Kusuhara M, Ulevitch RJ, Berk BC, and Lee JD (1996).Bigmitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J BiolChem 271, 16586-16590.
3. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, and Lee JD (1998). Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395, 713-716.
4. Zhou G, Bao ZQ, and Dixon JE (1995). Components of a new human protein kinase signal transduction pathway. J Biol Chem 270, 12665-12669.
5. Buschbeck M, Hofbauer S, Di CL, Keri G, and Ullrich A (2005). Abl-kinasesensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 6, 63-69.
6. Roberts OL, Holmes K, Muller J, Cross DA, and Cross MJ (2009). ERK5 and the regulation of endothelial cell function. Biochem Soc Trans 37, 1254-1259.
7. Wang X and Tournier C (2006). Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 18, 753-760.
8. Chiariello M, Marinissen MJ, and Gutkind JS (2000). Multiple mitogenactivated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 20, 1747-1758.
9. English JM, Pearson G, Hockenberry T, Shivakumar L, White MA, and Cobb MH (1999). Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 274, 31588-31592.
10. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, and Leung HY (2003).MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation,MMP-9 expression and invasion. Oncogene 22, 1381-1389.
11. Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, and Esparis-Ogando A (2009). Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4, e5565.
12. Sticht C, Freier K, Knopfle K, Flechtenmacher C, Pungs S, Hofele C, Hahn M, Joos S, and Lichter P (2008). Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia 10, 462-470.
13. Hayashi M, Tapping RI, Chao TH, Lo JF, King CC, Yang Y, and Lee JD (2001). BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem 276, 8631-8634.
14. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, Yang Y, Ulevitch RJ, and Lee JD (2004). Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 113, 1138-1148.
15. Pi X, Garin G, Xie L, Zheng Q, Wei H, Abe J, Yan C, and Berk BC (2005). BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1α. Circ Res 96, 1145-1151.
16. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, and Gutkind JS (2000). The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxiainducible factor 1α. Cancer Res 60, 4873-4880.
17. Sutton KM, Hayat S, Chau NM, Cook S, Pouyssegur J, Ahmed A, Perusinghe N, Le FR, Yang J, and Ashcroft M (2007). Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 26, 3920-3929.
18. Schweppe RE, Cheung TH, and Ahn NG (2006). Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses. J Biol Chem 281, 20993-21003.
19. Semenza GL (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007, cm8.
20. Kaelin WG Jr (2007). The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13, 680s-684s.
21. Borges J, Pandiella A, and Esparis-Ogando A (2007). Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal 19, 1473-1487.
22. Sanchez-Prieto R, Rojas JM, Taya Y, and Gutkind JS (2000). A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 60, 2464-2472.
23. de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias-Gonzalez L, Melgar-Rojas P, Galan-Moya EM, Garcia-Gil E, Garcia-Cano J, and Sanchez- Prieto R (2012). P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene 31, 1073-1085.
24. Palombella VJ, Rando OJ, Goldberg AL, and Maniatis T (1994). The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-785.
25. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, and Conaway JW (2000). Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97, 10430-10435.
26. Lee JD, Ulevitch RJ, and Han J (1995). Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun 213, 715-724.
27. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, and Kaelin WG Jr (1998). Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18, 732-741.
28. Buschbeck M and Ullrich A (2005). The unique C-terminal tail of the mitogenactivated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem 280, 2659-2667.
29. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr (2001). HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468.
30. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. (2001). Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472.
31. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, and Murai M (2007). Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α. Carcinogenesis 28, 529-536.
32. Lu Z, Xu S, Joazeiro C, Cobb MH, and Hunter T (2002). The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell 9, 945-956.
33. Sohn SJ, Sarvis BK, Cado D, and Winoto A (2002). ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277, 43344-43351.
34. Shishido T, Woo CH, Ding B, McClain C, Molina CA, Yan C, Yang J, and Abe J (2008). Effects of MEK5/ERK5 association on small ubiquitin-related modification of ERK5: implications for diabetic ventricular dysfunction after myocardial infarction. Circ Res 102, 1416-1425.
35. Woo CH, Shishido T, McClain C, Lim JH, Li JD, Yang J, Yan C, and Abe J (2008). Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res 102, 538-545.
36. Diaz-Rodriguez E and Pandiella A (2010). Multisite phosphorylation of Erk5 in mitosis. J Cell Sci 123, 3146-3156.
37. Inesta-Vaquera FA, Campbell DG, Tournier C, Gomez N, Lizcano JM, and Cuenda A (2010). Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 22, 1829-1837.
38. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, et al. (2006). Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxiainduced NFκB activity. Proc Natl Acad Sci USA 103, 18154-18159.
39. Fu J, Menzies K, Freeman RS, and Taubman MB (2007). EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J Biol Chem 282, 12410-12418.
40. Koditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C, Myllyharju J, Wenger RH, and Katschinski DM (2007). Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110, 3610-3617.
41. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG Jr, et al. (2005). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8, 155-167.
42. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, and Semenza GL (2011). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732-744.
43. Mikhaylova O, Ignacak ML, Barankiewicz TJ, Harbaugh SV, Yi Y, Maxwell PH, Schneider M, Van GK, Carmeliet P, Revelo MP, et al. (2008). The von Hippel-Lindau tumor suppressor protein and Egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol 28, 2701-2717.
44. Masson N, Willam C, Maxwell PH, Pugh CW, and Ratcliffe PJ (2001). Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 20, 5197-5206.
45. Huang J, Zhao Q, Mooney SM, and Lee FS (2002). Sequence determinants in hypoxia-inducible factor-1α for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 277, 39792-39800.
46. Landazuri MO, Vara-Vega A, Viton M, Cuevas Y, and Del PL (2006). Analysis of HIF-prolyl hydroxylases binding to substrates. Biochem Biophys Res Commun 351, 313-320.
47. Li D, Hirsila M, Koivunen P, Brenner MC, Xu L, Yang C, Kivirikko KI, and Myllyharju J (2004). Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1α-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases: substitution of 3,4-dehydroproline or azetidine-2-carboxylic acid for the proline leads to a high rate of uncoupled 2-oxoglutarate decarboxylation. J Biol Chem 279, 55051-55059.
48. Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, Roberts IS, Pugh CW, Werner H, and Macaulay VM (2007). The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26, 6499-6508.
49. Drew BA, Burow ME, and Beckman BS (2011). MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta 1825, 37-48.
50. Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, et al. (2011). Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 17, 845-853.
51. Klatte T, Lam JS, Shuch B, Belldegrun AS, and Pantuck AJ (2008). Surveillance for renal cell carcinoma: why and how?When and how often? Urol Oncol 26, 550-554.
52. Qian CN, Huang D, Wondergem B, and Teh BT (2009). Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 115, 2282-2289.
53. Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, Gomes S, Liu Y, Abe MK, Nor JE, et al. (2009). A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signalregulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. Blood 114, 4592-4600.
54. Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, Lehnert H, and Randeva HS (2009). Metformin decreases angiogenesis via NF-κB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res 83, 566-574.
55. Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Larsen T, and Haukaas SA (2009). The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol 182, 2144-2149.
56. Chen R, Yang Q, and Lee JD (2012). BMK1 kinase suppresses epithelialmesenchymal transition through the Akt/GSK3β signaling pathway. Cancer Res 72, 1579-1587.
57. Biyashev D, Veliceasa D, Kwiatek A, Sutanto MM, Cohen RN, and Volpert OV (2010). Natural angiogenesis inhibitor signals through Erk5 activation of peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 285, 13517-13524.
58. Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR III, Gray NS, and Lee JD (2010). Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18, 258-267.